anti-SSB were absent in the 4 patients. Biopsy of accessory salivary glands revealed the presence of a grade 4 lymphocytic sialadenitis according to the Chisholm and Masson classification in 3 patients, while the remaining case had a lymphocyte grade 2 sialadenitis. The evaluation of hepatic fibrosis did not reveal cirrhosis in the 4 cases.

**Conclusion:** The prevalence of Sicca syndrome during hepatitis C is estimated at 8% in our study. It was mainly reported in women with perimenopausal age and seems to be associated with cryoglobulinemia, a high viral load and an advanced fibrosis.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7584

---

**AB0530**

**THE EFFECT OF MYCOPHENOLATE MOFETIL ON NON-RENAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS FROM 2014 TO 2018: OBSERVATION STUDY FROM KOREAN LUPUS NETWORK (KORNET) REGISTRY**

Seona-Nyu Kim1, Jung-Yooon Choo2, Ji Hong Jung3, 1Catholic University of Daegu School of Medicine, Daegu, Korea, Rep. of (South Korea); 2Catholic University of Daegu School of Medicine, Daegu, Korea, Rep. of (South Korea); 3Daegu Catholic University Medical Center, Daegu, Korea, Rep. of (South Korea)

**Background:** Mycophenolate mofetil (MMF) has been established to be a potent therapeutic drug for regulate renal involvement in systemic lupus erythematosus (SLE). MMF might be beneficial to treat non-renal manifestations in SLE.

**Objectives:** The focus of this study is to identify the effect of MMF on non-renal manifestations in SLE.

**Methods:** The study population was total 409 SLE patients enrolled from Korean Lupus Network (KORNET) registry. The KORNET registry was followed-up annually and completed from baseline survey to the 2nd visit from 2014 to 2018. In the subgroup analysis, the effect of MMF on clinical features was also evaluated in 110 patients with histologically confirmed lupus nephritis (LN). The changes of clinical features including mucocutaneous lesions, arthritis, serositis, neurological disorder, and hematologic abnormalities were assessed between MMF and non-MMF groups during follow-up period. Statistical analysis was used by multiple comparison analysis, considering time, group, and interaction of follow-up time and treatment group.

**Results:** There was significant difference of malar rash and renal disorder between MMF and non-MMF groups considering time and group in total SLE patients (p = 0.025 and p < 0.001, respectively). In hematologic abnormalities, proportion of leukopenia was significantly different between two groups during follow-up periods (p<0.001, p=0.04, and p=0.004, respectively). In 110 LN patients, there was no difference of non-renal clinical features between them. In contrast, proportion of leukopenia in patients with LN was significantly different between two groups during follow-up periods (p=0.004, p=0.003, and p=0.004, respectively).

**Conclusion:** This study showed that MMF might be beneficial to treat for hematologic abnormalities in SLE.

**REFERENCES**


**Acknowledgement:** none

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.5268

---

**AB0531**

**OBESITY INCREASES THE INCIDENCE OF NEW-ONSET LUPUS NEPHRITIS AND ORGAN DAMAGE DURING FOLLOW-UP IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

Shin-Seok Lee1, Ji-Hyun Kang1, Sung-Eun Choi1, Haimuzi Xu1, Dong-Jin Park1, Cheonnam National University Hospital, Gwangju, Korea, Rep. of (South Korea)

**Background:** This study investigated the detrimental effects of obesity on clinical manifestations, disease activity, and organ damage in Korean patients with systemic lupus erythematosus (SLE).

**Methods:** We obtained data on 393 SLE patients from the Korean Lupus Network registry. Demographic variables, clinical manifestations, laboratory findings, Physician Global Assessment (PGA), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2000) and Systemic Lupus Interna
tional Collaborating Clinics Group (SLICC) damage index scores were recorded at the time of enrollment. The tests were repeated annually for 3 consecutive years. We divided the patients into groups according to their body mass index (BMI) using the Asia-Pacific classification (normal, BMI < 23; overweight, 23 ≤ BMI < 25; obese, BMI ≥ 25). Univariate and multivariate analyses were performed to assess the impact of obesity on clinical outcomes.

**Results:** Of the 393 patients, 59 (15.0%) were obese at the time of enrollment. Obese patients had more comorbidities, such as diabetes (P=0.002), hypertension (P=0.005), hyperlipidemia (P=0.005), and pulmonary hypertension (P=0.038) than non-obese patients. Nephritis at enrollment and newly developed nephritis during follow-up were more common in obese patients than in non-obese patients (P=0.002 and P=0.002, respectively). In addition, obese patients had higher daily and cumulative prednisolone doses (P=0.010 and P=0.010, respectively) and higher rates of intravenous cyclophosphamide (P=0.008), mycophenolate (P=0.030), tacrolimus (P=0.007), and cyclosporine (P=0.019) use than non-obese patients. Furthermore, the PGA and SLICC damage index scores were higher in obese patients than in non-obese patients (P=0.017 and P=0.039, respectively) for all 3 consecutive years. In the multivariate analysis, obesity was significantly associated with male gender (OR = 0.141, 95% CI: 0.047–0.419, P=0.001), newly developed nephritis (OR = 2.741, 95% CI: 1.080–6.957, P=0.034), and annual increase in SDI (OR = 2.185, 95% CI: 1.229–3.985, P=0.006).

**Conclusion:** Obese SLE patients had a higher incidence of newly developed nephritis and cumulative organ damage than non-obese patients. Therefore, lifestyle modifications, including those aimed at weight loss, should be recommended for these patients to improve their clinical outcomes.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.3430

---

**AB0532**

**SOLUBLE SIGLEC-5 IS A NOVEL SALIVARY BIOMARKER FOR PRIMARY SJOGREN'S SYNDROME**

Jennifer Lee1, Moon Young Kim1, Sung-Hwan Park1, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Division of Rheumatology, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea)

**Background:** Despite advances in the understanding of the pathogenesis, disease-specific biomarkers have not been included in the classification criteria for Primary Sjögren’s syndrome (pSS).

**Objectives:** Based on the microarray of peripheral blood mononuclear cell (PBMC) of pSS patients, we aimed to investigate whether sialic acid-binding immunoglobulin-like lectin (siglec)-5 might serve as a biomarker for pSS.

**Methods:** Microarray of PBMCs obtained from 26 pSS patients and 10 healthy control (HC)s was performed to screen potential biomarkers for pSS. The concentration of siglec-5 in saliva and sera was determined by ELISA. Clinical parameters related with pSS were obtained from pSS registry and correlation with salivary siglec-5 level was evaluated.

**Results:** Receiver operating curve (ROC) analysis was performed to determine cut-off value. A separate validation cohort consisted of subjects with suspicious pSS was evaluated to determine the performance.

**Results:** The level of salivary siglec-5/14 was significantly higher in pSS patients (n=26) compared with HC (n=6) and non-obese patients (n=78) (1346.8 [202.8-4280.0] pg/mL, 6.08 [0-134.0] pg/mL, and 195 [0-947.5] pg/mL, median [interquartile range], P<0.001). Furthermore, the PGA and SLICC damage index scores were not different between the groups. Clinical parameters were available in 170 patients in pSS registry. Salivary siglec-5 level negatively correlated with salivary flow rate ( Spearman’s rho: -0.420, P<0.001), and positively correlated with ocular surface score (rho: 0.331, P<0.001) and serum immunoglobulin G level (rho = 0.202, P=0.008). However, the level was not different between the groups.